You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
富祥藥業(300497.SZ):創新藥物研究公司完成工商變更登記並取得營業執照
格隆匯 03-08 17:06

格隆匯 3 月 8日丨富祥藥業(300497.SZ)公佈,公司20201227日召開第三屆董事會第十九次會議,審議通過了《關於合資設立創新藥物研究公司的議案》同意公司與上海凌凱醫藥科技有限公司(凌凱醫藥)共同出資設立創新藥物研公司,註冊資本為1億元,其中公司認繳出資4900萬元人民幣,佔創新藥物研究公司總股本的49%;凌凱醫藥認繳出資5100萬元人民幣,佔創新藥物研究公司總股本的51%凌凱醫藥是一家快速成長的醫藥研發生產服務外包的生產企業,致力於成為全球醫藥領域值得信賴的CDMO應商公司與凌凱醫藥合作,有助於公司開展CDMO業務,更快進入藥物研發服務市場,並將進一步增強公司的整體競爭力

近日,創新藥物研究公司完成了工商變更登記,取得了上海市浦東新區市場監管理局頒發的《營業執照》。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account